Maximizing productivity in biopharmaceutical research and clinical development

Researchers utilizing immunoassays throughout the biotherapeutics development process are looking for:

• High quality data for confident decisions
• Fast turn around time to results
• Rapid assay development
• Robust assays
• Low sample consumption
• High throughput 

We present three examples that show how Gyrolab^® systems contribute to developing biopharmaceutical drugs faster and with less cost and effort.

Case study 1: Obtaining an entire PK profile from a single mouse

Case study 2: Earlier and more sensitive detection of drug-induced kidney toxicity in preclinical studies

Case study 3: Ramping up Phase II/III PK studies to meet critical deadlines